Cencora, known for most of its modern history as AmerisourceBergen, is a company whose scale is entirely disproportionate to its public visibility. The modern corporate leviathan was formed in 2001 through the merger of AmeriSource Health and Bergen Brunswig, two major regional drug distributors. This merger was part of a relentless, multi-decade wave of consolidation within the pharmaceutical supply chain. Today, Cencora operates as part of an impenetrable "Big Three" oligopoly (alongside McKesson and Cardinal Health) that collectively controls roughly 90% of the entire pharmaceutical distribution market in the United States, effectively acting as the indispensable physical bridge between drug manufacturers and local pharmacies.
The Economics of the Middleman
The pharmaceutical wholesale business is a logistical marvel operating on razor-thin economics. An independent pharmacy cannot efficiently negotiate with, and receive daily shipments from, 500 different drug manufacturers (like Pfizer, Merck, and Eli Lilly). Instead, Cencora acts as the prominent central aggregator. It buys billions of dollars of drugs in bulk, stores them in automated, strong regional distribution centers, and uses a considerable fleet of couriers to deliver exact, mixed orders of medications to tens of thousands of pharmacies overnight. Because they are essentially just moving boxes, the net profit margin is often less than 1%. The only way the business model survives is through very high, hundreds-of-billions-of-dollars scale.
The Walgreens Alliance
In 2013, seeking guaranteed volume to support its thin margins, the company signed a 10-year partnership (later extended through 2029) with Walgreens Boots Alliance. As part of the deal Walgreens received the right to buy an equity stake, which it later sold down to about 6% by 2025, Cencora secured the exclusive, multi-billion-dollar contract to supply the vast majority of Walgreens' major network of retail pharmacies globally. This strategic alliance insulated Cencora from the threat of Walgreens building its own internal distribution network and guaranteed the major, daily volume required to keep its distribution centers operating at maximum efficiency.
The Pivot to Specialty Drugs
While moving considerable pallets of generic ibuprofen to retail pharmacies provides the base volume, it generates very little profit. To drive actual earnings growth, Cencora pivoted toward "Specialty Distribution." Specialty drugs are the most complex, expensive medications on earth, often complex biologics used to treat cancer or rare genetic diseases. These drugs often cost tens of thousands of dollars per dose and require strict "cold chain" logistics (they must be maintained at exact temperatures or they are destroyed). Cencora dominates this specialized niche, providing complex logistics and patient support services directly to prominent hospital systems and oncology clinics, capturing significantly higher profit margins than the traditional retail business.
The Opioid Crisis and Rebranding
Because the Big Three distributors physically moved the vast majority of prescription opioids during the devastating American opioid epidemic, they faced strong legal and political reckoning. Cencora, along with McKesson and Cardinal Health, faced thousands of lawsuits from states and municipalities, arguing the companies failed to monitor and report suspiciously large orders of addictive painkillers to small, rural pharmacies. In 2021 the three distributors agreed to a national settlement of about $21 billion, payable over 18 years. In 2023 AmerisourceBergen rebranded as Cencora to bring its U.S. and international businesses under one name.
From Distributor to Specialty Platform
Under CEO Robert Mauch, who took over in October 2024, Cencora has bought about 85% of Retina Consultants of America and a majority of OneOncology, giving it management of physician networks that use costly specialty drugs. In February 2026 it agreed to merge MWI Animal Health with Covetrus. Fiscal 2025 revenue reached $321.3 billion, and in the June 2026 quarter revenue rose 5.1% to $84.8 billion.
